TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors (68-DOTANOC-GEP)

Nantes University Hospital (NUH)

Status

Completed

Conditions

Patients With Gastroenteropancreatic Neuroendocrine Tumors

Treatments

Drug: 68-Ga-DOTANOC

Study type

Interventional

Funder types

Other

Identifiers

NCT01747096

BRD/11/05-K

Details and patient eligibility

About

Evaluation of the diagnostic performance of PET / CT with 68Ga-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors with comparison with other techniques used in routine clinical practice (octreoscan ® ; multiphase SPECT / CT, MRI or endoscopy).

Therapeutic impact and safety of PET / CT with 68Ga-DOTANOC will also be assessed. Expected results are a confirmation of the superiority of 68Ga-PET DOTANOC versus scintigraphy octreoscan ®, with a potential impact on the therapeutic management of patients.

Enrollment

130 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age over 18 years
effective contraception or exclusion of pregnancy dosage of beta-HCG in women of childbearing age
Fortuitous discovery of suggestive tumors of TE-GEP with well documented conventional imaging (multiphase CT; MRI, US endoscopy) associated or not associated with clinical or biological signs of TE-GEP tumors (increase in tumor markers) OR
Histologically proven GEP-TE (WHO classification 2010 (26) well differentiated in the initial staging OR
Suspicion of recurrence or progression of well differentiated TE-GEP tumors on conventional imaging or laboratory tests (increase in tumor markers) OR
Clinical or biological syndrome strongly suggestive of digestive endocrine disease without identification of lesions with conventional imaging
Informed consent and patient's written
Affiliation to an insurance

Exclusion criteria

Multiple endocrine neoplasia
TE GEP tumor not differentiated
Pregnancy and lactation
Persons protected by law
Restlessness, inability to lie still hold at least 1 hour; Claustrophobia
Poor compliance predictable or inability to undergo medical test for geographical, social or psychological
Treatment with radiotherapy, chemotherapy or other antitumor treatment within 6 weeks of previous morphological and scintigraphic examinations. In case of treatment with somatostatin analogues delayed, scans will be performed 4 weeks after the last injection. However, a shorter period may be observed to avoid to do again the initial assessment exams.
malignancy except basal cell cancers and cancer in situ of the cervix
Contraindication of injection of a contrast agent necessary for the production of multiphase scanner.
Patients who had a CT scan without injection of contrast material can not participate in the study